CollPlant Biotechnologies
CLGN
21 hedge funds and large institutions have $29.5M invested in CollPlant Biotechnologies in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 4 closing their positions.
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
40% more funds holding
Funds holding: 15 → 21 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.22% less ownership
Funds ownership: 1.91% → 1.69% (-0.22%)
11% less capital invested
Capital invested by funds: $33.1M → $29.5M (-$3.62M)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
88% less call options, than puts
Call options by funds: $3K | Put options by funds: $26K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IMOV
Investment Management of Virginia
Richmond,
Virginia
|
+$797K |
| 2 |
Zurich Cantonal Bank
Zurich,
Switzerland
|
+$439K |
| 3 |
KWM
Kingsview Wealth Management
Grants Pass,
Oregon
|
+$329K |
| 4 |
LPL Financial
San Diego,
California
|
+$264K |
| 5 |
HF
HRT Financial
New York
|
+$241K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$3.08M |
| 2 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
-$1.2M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$461K |
| 4 |
Renaissance Technologies
New York
|
-$169K |
| 5 |
ACM
ACT Capital Management
Wayne,
Pennsylvania
|
-$127K |
CLGN Hedge Fund Activity: Q4 2021 in Review
21 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in CollPlant Biotechnologies (CLGN) for Q4 2021, worth a combined $29.5M — down 11% from $33.1M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CLGN positions and 4 closed out — a net gain of 6 holders — while 4 added to existing stakes and 7 trimmed.
The largest buyer was Investment Management of Virginia, adding an estimated $797K. The largest seller was State Street, exiting entirely with an estimated $3.08M sold.
- 21 institutional investors held CollPlant Biotechnologies (CLGN) as of Q4 2021, up from 15 in Q3 2021.
- Funds reported $29.5M of CollPlant Biotechnologies stock for Q4 2021, down 11% quarter-over-quarter.
- 10 funds opened new CollPlant Biotechnologies positions in Q4 2021 and 4 closed out, a net change of +6 holders.
- The largest CollPlant Biotechnologies buyer in Q4 2021 was Investment Management of Virginia, an estimated $797K added.
- The largest CollPlant Biotechnologies seller in Q4 2021 was State Street, an estimated $3.08M sold.
Based on aggregated 13F filings for Q4 2021.